What is NextCure?
NextCure is dedicated to the discovery and development of novel, first-in-class immunomedicines. The company's core mission revolves around harnessing the power of the immune system to combat cancer and other debilitating immune-related conditions. By focusing on innovative therapeutic strategies, NextCure aims to address unmet medical needs and improve patient outcomes in challenging disease areas. The company's commitment to pioneering new treatments positions it as a key player in the biopharmaceutical landscape, driving forward advancements in immunotherapy.
How much funding has NextCure raised?
NextCure has raised a total of $324.8M across 4 funding rounds:
Series A
$67M
Stock Offering
$86.3M
Stock Offering
$150M
Other Financing Round
$21.5M
Series A (2016): $67M with participation from Lilly Asia Ventures, Sofinnova Ventures, Pfizer Inc., OrbiMed, Alexandria Venture Investments, and Canaan Partners
Stock Issuance/Offering (2019): $86.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $150M, investors not publicly disclosed
Other Financing Round (2025): $21.5M featuring Exome Asset Management, Ikarian Capital, and Squadron Capital Management
Key Investors in NextCure
Exome Asset Management
Exome Asset Management is an investment firm that likely focuses on opportunities within the biotechnology and life sciences sectors, potentially specializing in companies with novel genetic or therapeutic platforms.
Ikarian Capital
Ikarian Capital is an investment firm with a probable focus on the healthcare and biotechnology industries, seeking to support companies with innovative technologies and strong growth potential.
Squadron Capital Management
Squadron Capital Management is an investment entity that may concentrate on strategic investments within the life sciences, aiming to back companies poised for significant advancements or market impact.
What's next for NextCure?
The recent major strategic investment signals a pivotal phase for NextCure, likely enabling the acceleration of its clinical development programs and the expansion of its research initiatives. This infusion of capital is expected to support the progression of its lead drug candidates through critical clinical trials and potentially facilitate the exploration of new therapeutic targets. The company's strategic focus on immunomedicines, coupled with substantial financial backing, positions it for continued growth and innovation in the competitive biopharmaceutical sector. Future developments will likely center on clinical trial results and potential regulatory milestones.
See full NextCure company page
